lifestyle.realie.org

Author: Hyperscale Data Inc.

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study in a Trial Conducted at Massachusetts General Hospital

April 7, 2026
Hyperscale Data Receives $26.6 Million of Cash Related to Litigation Settlement; Cash Receipt Represents a Significant Liquidity Event for the Company

April 2, 2026
TurnOnGreen, Inc. Reports 2025 Financial Results Following Form 10-K Filing

April 1, 2026
Hyperscale Data Enters into Agreement to Expand Michigan AI Data Center Campus with 48.5 Acre Acquisition

March 30, 2026
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 “Lithium in Brain” Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

March 26, 2026
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 “Lithium in Brain” Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

March 16, 2026
TurnOnGreen and TESCO Partner to Deploy DC Fast Charging Infrastructure Across Indiana Key Travel Corridors

March 11, 2026
TurnOnGreen Completes EV Charging Project at Hi-Desert Medical Center with Grant Funding from the Mojave Desert Air Quality Management District

March 5, 2026
TurnOnGreen’s Digital Power Corporation Secures Design Win with Major Post-Production Technology Provider

March 3, 2026
Hyperscale Data Reaffirms Digital Asset Treasury Policy Amid Bitcoin Volatility; Continues Weekly Dollar-Cost-Averaging Purchases

February 2, 2026